Duchenne muscular dystrophy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• DMD 9
• ATM 0
• SIRT1 0
• EGFR 0
• AMPK 0
• HDAC 0
• mTOR 0
• SGLT2 1
• TNF 0
• CFTR 1
• CTLA-4 0
• G6PD 0
• GLP-1 0
• HTT 1
• IL-23 0
• IL-6 0
• NF1 1
• NRF2 0
• PINK1 0
• PPAR 0
• SMN1 1
• STK11 0
• TTR 1
• YAP 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R21

  Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity

  University of Southern California· Los Angeles, United States· US$211,650 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · R44

  IND-enabling program for novel stimulant FBD-400

  Firebird Pharmaceuticals, Inc.· Boston, United States· US$1,654,275 awarded in fiscal year 2026· until May 2028

• NIH NINDS · R56

  Treg-mediated tolerance of dystrophin immunity

  University of California-Irvine· Irvine, United States· US$549,500 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · U01

  Advancing Ex Vivo Gene Therapy: IND-Enabling Studies for ASAH1-related SMA-PME

  Cedars-Sinai Medical Center· Los Angeles, United States· US$825,159 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R01

  Targeting protein N-terminal methyltransferase in muscle diseases

  Purdue University· West Lafayette, United States· US$587,757 awarded in fiscal year 2026· until Jun 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Syriac Education, Abbasid Times: Reclaiming the Place of Syriac Intellectual Training under Muslim Rulers (SEAT)

  Universita Degli Studi di Catania· Catania, Italy· EU contribution €209,483· until Feb 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophies (StemAAV)

  Institut Pasteur· Paris, France· EU contribution €150,000· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  SKeletal Muscle - REgulation of FORce and Maturation through Tubulin isotypes (SKM-REFORMAT)

  Universite Lyon 1 Claude Bernard· Villeurbanne Cedex, France· EU contribution €242,261· until Jan 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Exploiting Transcriptional Adaptation to Develop New Genetic Compensation-based Therapies (TA2TRSQ)

  Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev· Munchen, Germany· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Deciphering the role of protein S-palmitoylation in skeletal muscle physiopathology (MyoPALM)

  Universita Degli Studi di Padova· Padova, Italy· EU contribution €320,924· until Aug 2027· 2 countries

10 of 218 running projects, newest first. Listed amounts together: US$115.0m + €16.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Organoids 3
• CRISPR-Cas Systems 13
• Gene Expression Profiling 7
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 13
• Metabolomics 1
• Mass Spectrometry 2
• Immunohistochemistry 3
• Magnetic Resonance Imaging 19
• Machine Learning 2
• Cohort Studies 8

• Conformable Microelectrode Arrays Integrated with a Scoop-Shaped Slide-Well for Dynamic Electrophysiological Profiling of Patient-Derived Cardiac Organoids.

  Adv Sci (Weinh), Mar 2026

• Patient-Derived 3D Bioprinted Cardiac Organoid Constructs Reveal Key Pathological Features of Duchenne Muscular Dystrophy.

  Adv Healthc Mater, Feb 2026

• Proteomics of Duchenne Muscular Dystrophy Patient iPSC-Derived Skeletal Muscle Cells Reveal Differential Expression of Cytoskeletal and Extracellular Matrix Proteins.

  Cells, Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.